Drugs / SB-318
SB-318
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02702115 | May 2017 → Nov 2021 | mucopolysaccharidosis type 1 | Sangamo Therapeutics | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SB-318 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02702115 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “SB-318, a rAAV2/6-based Gene Transfer” NCT02702115 ↗ |
| Route | Intravenous | “administered via intravenous (IV) infusion” NCT02702115 ↗ |
| Target | IDUA | “It inserts a correct copy of the α-L-iduronidase (IDUA) gene into the Albumin locus in hepatocytes” NCT02702115 ↗ |